New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

Today's Free Fly Stories
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | all day >>
07:55 EDTAEOAmerican Eagle Q4 result were solid, says Susquehanna
Susquehanna said American Eagle posted solid Q4 results due to its improved merchandise position, stringent inventory control, and expense management. Susquehanna maintained its Positive rating and raised its price target to $20 from $19 on American Eagle shares.
07:55 EDTEQREquity Residential upgraded at Evercore ISI
Subscribe for More Information
07:55 EDTDBDeutsche Bank co-CEO says not changing universal bank model, Reuters says
Subscribe for More Information
07:54 EDTPCRXFDA PDUFA Date for Pacira's Exparel is March 5, 2015
07:53 EDTUDRUDR, Inc. downgraded to Hold from Buy at Evercore ISI
Subscribe for More Information
07:51 EDTXOMExxon Mobil downgraded at Evercore ISI
Subscribe for More Information
07:51 EDTTENXTenax Therapeutics highlights two scientific articles on Levosimendan
Tenax Therapeutics highlighted two recently-published scientific articles on the potential benefits of its lead candidate, levosimendan, in patients undergoing cardiac surgery. The company is currently enrolling patients in its Phase 3 LEVO-CTS trial for levosimendan, a double-blind, randomized, placebo-controlled study that will evaluate the use of levosimendan administered before and during cardiac surgery to reduce the incidence of low cardiac output syndrome and associated morbidity and mortality. “We believe the conclusions drawn in these publications are highly supportive of our LEVO-CTS trial design and expectations regarding our study results,” said the company. In one article, a panel of 27 experts from 18 countries support the LEVO-CTS study design in several ways – specifically, the consensus publication recommends pre-operative dosing and use in low ejection fraction coronary artery bypass and valve surgery patients. Their conclusion also generally supports the LEVO-CTS study endpoints, stating. The second article studied 46 trials published between 1995-2014 and concluded that levosimendan appears to be the most efficacious inodilator product to improve survival when used in cardiac surgery patients.
07:50 EDTTreasury Market Outlook: Treasuries are little changed to slightly lower
Subscribe for More Information
07:49 EDTOCR, NVSOmnicare SCG ACS to provide services for Novartis Farydak
Subscribe for More Information
07:49 EDTTSLTrina Solar price target raised to $15 from $13 at RBC Capital
RBC Capital increased its price target on Trina Solar as the firm thinks the company's fundamentals remain strong after it reported in-line revenue but higher than expected EPS. RBC notes that the company provided 2015 project grid connection guidance of 700-750 MW, versus the 283 MW of its projects that were connected last year. RBC expects the spin off of Trina's project holding vehicle to provide a catalyst in 2016. It keeps an Outperform rating on the shares.
07:48 EDTFREDFred's reports February SSS approximately flat
Subscribe for More Information
09:05 EDTAFL, RDHL, LLTP, ONVO, AFL, RDHL, LLTP, ONVOPR Newswire to hold a virtual conference
Subscribe for More Information
07:46 EDTFLDMFluidigm remains a top small-cap pick at Leerink
Leerink says it has increased conviction in Fluidigm's growth prospects following its recent due diligence, mainly due to the upside opportunity offered by the Polaris instrument for single cell analysis. It raised its price target for shares to $52 from $47 and reiterates Fluidigm as one of its top small-cap picks.
07:46 EDTECB leaves key interest rates unchanged
Subscribe for More Information
07:46 EDTFORForestar Group says board, management evaluating strategic alternatives
Subscribe for More Information
07:45 EDTFORForestar Group reports Q4 adjusted EPS 32c, consensus (3c)
Reports Q4 revenue $80.32M, consensus $67.38M.
07:45 EDTFORForestar Group sees FY15 residential lot sales volume 1,800-1,900 lots
Subscribe for More Information
07:45 EDTMCD, SBUX, ANFI, CAKE, GPC, HBI, DNKN, AZO, NDLS, SWHC, SSI, VIPSUBS to hold a conference
Subscribe for More Information
07:44 EDTPGProcter & Gamble management to meet with Deutsche Bank
Meeting to be held in Montreal on March 5 hosted by Deutsche Bank.
07:43 EDTBTEBaytex Energy reports Q4 FFO C$1.47 vs. C$1.17 last year
Subscribe for More Information
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | all day >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use